Boosters Miss Growth Expectations Despite China COVID Surge
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
You may also be interested in...
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.